| Source: |
| Type: |
TRAF1 is an adaptor protein in TNF receptor superfamily signaling that modulates NF-κB, MAPK, and apoptotic pathways. Unlike other TRAFs, TRAF1 lacks intrinsic E3 ubiquitin ligase activity, acting instead as a regulatory scaffold. In cancer, TRAF1 is best viewed as a pro-survival, anti-apoptotic signal amplifier, especially in immune-related and hematologic malignancies.
Expression Pattern in Cancer
-Low or absent in most normal tissues
-Inducible by NF-κB
-Overexpressed in many cancers, especially:
-B-cell lymphomas (CLL, Hodgkin lymphoma, DLBCL)
-Multiple myeloma
-Some solid tumors with inflammatory microenvironments
-High TRAF1 expression correlates with:
-Therapy resistance
-Immune-evasive phenotypes
-Poor prognosis (context-dependent)
|
| CLL is a type of cancer that affects the lymphoid cells, which are a type of white blood cell. It is characterized by the accumulation of mature, but dysfunctional, lymphocytes in the bone marrow, lymph nodes, and spleen. CLL is typically a slow-growing disease, and many patients may not experience symptoms for years after diagnosis. |
| 5150- | GamB, | Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway |
| - | in-vitro, | CLL, | KBM-5 | - | in-vitro, | Nor, | HEK293 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:50 Cells:% prod#:% Target#:1437 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid